• Are Insiders Buying AbbVie Inc. (NYSE:ABBV) Stock?
    Simply Wall St.

    Are Insiders Buying AbbVie Inc. (NYSE:ABBV) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Cannabis Roundup: HEXO, CRON, CURA, and ACB
    Market Realist

    Cannabis Roundup: HEXO, CRON, CURA, and ACB

    Bad news on the trade war front appears to have led to a fall in the broader US equity markets today. Cannabis ETFs were also trading in the red.

  • One More Marijuana ETF on the Block
    Zacks

    One More Marijuana ETF on the Block

    As Global X launches a fresh pot ETF, let's explore the product in detail.

  • Mayor to Regulate Cannabis Stores in Chicago
    Market Realist

    Mayor to Regulate Cannabis Stores in Chicago

    Chicago mayor Lori Lightfoot has introduced an ordinance regulating cannabis stores, keeping them away from the city's central business district.

  • Is GW Pharmaceuticals (GWPH) Outperforming Other Medical Stocks This Year?
    Zacks

    Is GW Pharmaceuticals (GWPH) Outperforming Other Medical Stocks This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • Can Altria Battle Dwindling Cigarette Sales & Vaping Worries?
    Zacks

    Can Altria Battle Dwindling Cigarette Sales & Vaping Worries?

    Altria (MO) is reeling under regulatory pressures in the tobacco industry. However, higher pricing is likely to provide support.

  • Neogen Forms Partnership With IGS to Enhance Beef Profile
    Zacks

    Neogen Forms Partnership With IGS to Enhance Beef Profile

    Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.

  • Marijuana Legalization: O’Rourke Blazes His 2020 Campaign
    Market Realist

    Marijuana Legalization: O’Rourke Blazes His 2020 Campaign

    Democratic presidential candidate Beto O’Rourke is known for voicing his opinion on federal marijuana legalization. He supports marijuana legalization.

  • Investing.com

    Stocks - U.S. Futures Rise as Trade Progress Monitored

    Investing.com - U.S. futures rose slightly on Friday, amid further tentative signs of detente between the U.S. and China on trade.

  • Cannabis Roundup: CTST, CURA, CRON, and WEED
    Market Realist

    Cannabis Roundup: CTST, CURA, CRON, and WEED

    Today, the US cannabis markets were trading a little higher than we have seen in the recent past. The Federal Reserve cut interest rates by 25 points.

  • Tilray, Inc. (TLRY) Stock Moves -1.71%: What You Should Know
    Zacks

    Tilray, Inc. (TLRY) Stock Moves -1.71%: What You Should Know

    Tilray, Inc. (TLRY) closed at $29.96 in the latest trading session, marking a -1.71% move from the prior day.

  • Cannabis 2.0: Aurora Cannabis Gears Up for Edibles Market
    Market Realist

    Cannabis 2.0: Aurora Cannabis Gears Up for Edibles Market

    Cannabis 2.0 legalization will take place in Canada next month. Cannabis players are gearing up to expand in the edibles market.

  • The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
    Zacks

    The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

    The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK

  • Altria Falls 3%
    Investing.com

    Altria Falls 3%

    Investing.com - Altria (NYSE:MO) fell by 3.13% to trade at $39.56 by 14:18 (18:18 GMT) on Thursday on the NYSE exchange.

  • CBD Products: McConnell Wants FDA to Ease Regs
    Market Realist

    CBD Products: McConnell Wants FDA to Ease Regs

    Earlier this week, Senator Mitch McConnell submitted a proposal that would require the FDA to set a policy for the sale of hemp CBD products.

  • Medtronic Receives European Nod for Glucose Monitoring System
    Zacks

    Medtronic Receives European Nod for Glucose Monitoring System

    Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.

  • Investing.com

    NewsBreak: FDA in Criminal Vaping Probe; 530 Sickened

    Investing.com - The U.S. Food and Drug Administration said Thursday its enforcement arm is involved in a criminal probe of e-cigarettes, The Washington Post reported.

  • Canopy Growth Stock Rises, Oppenheimer Initiates Coverage
    Market Realist

    Canopy Growth Stock Rises, Oppenheimer Initiates Coverage

    Oppenheimer analyst Rupesh Parikh initiated coverage on Canopy Growth stock. The analyst gave a “perform” rating with no target price.

  • The Cannabis Market Is Looking Up, Even If Cannabis Stocks Aren’t
    Bloomberg

    The Cannabis Market Is Looking Up, Even If Cannabis Stocks Aren’t

    (Bloomberg Opinion) -- Almost exactly a year ago, a small Canadian cannabis company was generating a lot of buzz (sorry, couldn’t resist the pun). Despite trifling quarterly revenue of $9.7 million, Tilray Inc.’s market capitalization got so high (sorry again, I’ll stop) that it briefly eclipsed that of major companies people have actually heard of, such as American Airlines Group Inc.The boom quickly faded — not surprising, given how senseless it looked even in the moment — and Tilray’s stock has continued to decline. And the cannabis sector has also stumbled recently.But this dampened enthusiasm for marijuana stocks does not necessarily reflect fading prospects for the marijuana market, which still has promise. Instead, it is related to short-term challenges associated with a bumpy rollout of legal marijuana in Canada, which are making it hard for winners to quickly emerge.In October 2018, Canada became only the second country to legalize recreational marijuana. But it’s still not particularly easy for Canadian consumers to get their hands on cannabis, as the pace of dispensary openings has been slow.In a research note, Vivien Azer of Cowen & Co. offered this example to demonstrate how sparse dispensaries are, on a per capita basis, in Ontario, the country’s most populous province:Kenneth Shea, a Bloomberg Intelligence analyst, notes that even within the small ecosystem of stores, it’s been tough in early days to match supply with demand, with dispensaries sometimes sold out of higher-quality strains.Meanwhile, average prices for legal cannabis remain well above prices on the illegal market. If the legal product is still inconvenient to buy, and if the illegal product is cheaper, then it follows that dispensary sales of cannabis haven’t exactly soared yet.In this fast-evolving, Wild West of a market, some industry heavyweights have ended up disappointing investors with their recent sales or profitability figures. Aurora Cannabis Inc., for one, had said in May it was on track to achieve growth in adjusted earnings before interest, taxes, depreciation and amortization in the fourth quarter. When it reported results last week, it said it had failed to meet this target, citing “challenges at the retail level” that were “beyond its control.”That doesn’t mean there aren’t realistic paths for the industry’s leading companies to earn more revenue as they bolster their capacity and as the forthcoming addition of more Canadian retail locations gives them a chance to court more customers. Plus, some of the biggest opportunity in Canada is yet to come: In the first year of legalization, the country allowed sales of only certain cannabis products, including smokeable flower and oils. Edibles and beverages are to be phased in later this year, potentially drawing interest from a wider swath of consumers who aren’t interested in smoking but are curious about cannabis.Looking beyond Canada, forecasts suggest medical and recreational markets will continue to open up worldwide, providing ample opportunity for long-term growth if these companies can ramp up their supply quickly and build compelling brands.So, a year after Tilray’s wild ride, investors seem to be getting more cautious about cannabis stocks. It’s hard to know which companies will eventually prosper — and it’s risky to try to make a quick investing buck from it. The outlook for the industry as a whole, however, remains plenty upbeat.To contact the author of this story: Sarah Halzack at shalzack@bloomberg.netTo contact the editor responsible for this story: Michael Newman at mnewman43@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Sarah Halzack is a Bloomberg Opinion columnist covering the consumer and retail industries. She was previously a national retail reporter for the Washington Post.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • What Kind Of Shareholders Own The Green Organic Dutchman Holdings Ltd. (TSE:TGOD)?
    Simply Wall St.

    What Kind Of Shareholders Own The Green Organic Dutchman Holdings Ltd. (TSE:TGOD)?

    A look at the shareholders of The Green Organic Dutchman Holdings Ltd. (TSE:TGOD) can tell us which group is most...

  • Tilray’s Dubious Anniversary Marks 90% Stock Decline
    Bloomberg

    Tilray’s Dubious Anniversary Marks 90% Stock Decline

    (Bloomberg) -- It was arguably the peak of pot-stock volatility, and also a peak that Tilray Inc. has never come close to hitting since.One year ago today, Tilray took the wildest ride of its existence, nearly doubling to $300 before wiping out the entire gain in less than an hour, then climbing back to finish 40% above where it started.Twelve months later, the stock is down about 90% from that intraday high, erasing more than $17 billion of market value. It’s one of the most dramatic reversals ever in a sector that’s sagged more than 40% since March.Call it a return to earth for cannabis. Tilray’s price-to-sales ratio had reached levels 25 times higher than those of tech giants Amazon.com Inc. and Apple Inc. last September, the month before Canada legalized recreational use.The decline hasn’t deterred short sellers, who’ve collectively made $112 million off their Tilray positions this year, according to financial analytics firm S3 Partners. Tilray’s short interest stood at $256 million or 38% of float as of Sept. 18, according to S3 Partners’ data.A variety of factors have weighed on pot stocks this year, including bigger-than-expected losses at many of the largest companies, regulatory breaches at one-time industry darling CannTrust Holdings Inc., and antitrust reviews of U.S. acquisitions.The decline has shaved a significant amount off the sector’s market value, with the BI Global Cannabis Competitive Peers index losing about $25 billion since late April.To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Divya Balji, Morwenna ConiamFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Bull of the Day: GW Pharmaceuticals (GWPH)
    Zacks

    Bull of the Day: GW Pharmaceuticals (GWPH)

    Bull of the Day: GW Pharmaceuticals (GWPH)

  • Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know
    Zacks

    Aurora Cannabis Inc. (ACB) Flat As Market Gains: What You Should Know

    In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $5.27, marking no change from the previous day.

  • Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know

    Cronos Group (CRON) closed the most recent trading day at $10.96, moving -1.7% from the previous trading session.

  • Top Analyst Reports for AbbVie, Union Pacific & CSX
    Zacks

    Top Analyst Reports for AbbVie, Union Pacific & CSX

    Top Analyst Reports for AbbVie, Union Pacific & CSX